Says continues to invest in R&D at “competitive levels.” Says plans to continue to increase dividend annually. Expects Innovative Medicine sales growth “slightly stronger” in 1H24 vs. 2H24. Expects FY24 MedTech operational sales growth “relatively consistent” throughout the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson (NYSE:JNJ) Drops Despite Q4 Beat
- Options Volatility and Implied Earnings Moves Today, January 23, 2024
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Options Volatility and Implied Earnings Moves This Week, January 22 – January 26, 2024
- JNJ Earnings this Week: How Will it Perform?